Lilly Unfazed as CVS Picks Novo’s Aspect in Weight problems Market Battle

Eli Lilly has pulled forward of rival Novo Nordisk within the weight problems market, in response to analysts, simply as CVS Well being selected sides within the fierce head-to-head battle.

Lilly booked $2.31 billion in gross sales for Zepbound in the course of the first quarter, in response to the corporate’s earnings report issued Thursday. However on the identical day, CVS Well being introduced that rival med Wegovy could be made out there on its formulary for simply $499 monthly.

“We’re not shocked this sort of factor was introduced,” Lilly CEO David Ricks mentioned on an investor name Thursday morning. “If we have a look at what’s taking place available in the market, we’re fairly deep right into a alternative cycle, significantly on weight problems.”

Ricks is assured that Zepbound is gaining market share on the expense of Wegovy. “A lot of the development within the class is occurring with our profit,” the CEO mentioned. Novo is not going to report its first quarter earnings till Could 7, however Lilly’s weight problems portfolio eclipsed the Danish rival final quarter.

Calling it “vital,” Ricks mentioned Lilly want to broaden its main pay section, the place sufferers pay for his or her drugs themselves with out insurance coverage. Lilly affords Zepbound to sufferers via a direct-to-consumer program referred to as LillyDirect. However Ricks dismissed the CVS endorsement and mentioned Lilly want to see expanded selection and entry within the main pay market, so “this sort of factor isn’t too fascinating to us.”

Truist Securities analysts, nevertheless, mentioned CVS’ selection will trigger some near-term strain on Lilly. Novo additionally introduced a take care of telehealth pharmacy Hims & Hers this week pricing Wegovy at $599.

One analyst, Steve Scala, who has a historical past of throwing robust questions at pharma executives, reminded executives that Lilly had used an analogous formulary tactic for its earlier psoriasis drugs Taltz.

Ricks mentioned he didn’t bear in mind the state of affairs that method, however these formulary battles sometimes play out when there are a number of choices for sufferers with related scientific profiles. Within the case of Taltz, Lilly was the come-from-behind firm. Zepbound, although it trailed Wegovy to market, is pushing boundaries on innovation, Ricks asserted.

Discover the Proper Mechanism

Like all of its friends, Lilly addressed the specter of tariffs, too. Ricks urged the Trump administration to contemplate tax coverage modifications as an alternative of tariffs, just like a few of his friends like Johnson & Johnson’s Joaquin Duato.

“We assist the U.S. authorities’s objectives to extend home funding. Nevertheless, we don’t imagine tariffs are the best mechanism,” Ricks mentioned.

The at the moment introduced tariffs is not going to have an effect on Lilly’s 2025 monetary outlook, the CEO famous, however expansions into different areas or elevated retaliatory tariffs may change that. Lilly has already introduced $27 billion in U.S. manufacturing expansions.

“We urge the administration to barter offers with key buying and selling companions as quickly as attainable, degree the enjoying area for American exporters like Lilly and take away dangerous tariffs and non-tariff market entry obstacles within the developed economies.”

Elsewhere, Lilly withdrew an utility for tirzepatide (the lively ingredient in Zepbound) in coronary heart failure with preserved ejection fraction (HFpEF) after the FDA requested a further confirmatory scientific trial. The GLP-1 was submitted to the FDA and in Europe on this indication in November 2024 after the Part III SUMMIT trial confirmed a 38% drop within the relative danger of coronary heart failure outcomes.

Chief Scientific Officer Dan Skovronsky mentioned the trial confirmed “a extremely robust and profound profit for sufferers,” so he was disenchanted within the FDA’s resolution to require one other trial. Lilly is unlikely to conduct such a big trial as a result of there’s loads of proof from scientific research in associated indications like weight problems that may assist the profit in coronary heart failure, Skovronsky mentioned.

“It’s form of arduous to consider the inducement for doing massive consequence trials on this inhabitants that’s already lined below an present indication. The advantages are properly understood,” the CSO continued. “Simply do not forget that the entire sufferers on this trial indication are already lined below the weight problems indication. So it’s not a brand new inhabitants to deal with.”

However the resolution may have a chilling impact on funding in HFpEF, Skovronsky added, noting this is a sign with an enormous unmet want.